{"id":59135,"date":"2024-04-02T10:03:35","date_gmt":"2024-04-02T08:03:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/"},"modified":"2024-04-02T10:03:35","modified_gmt":"2024-04-02T08:03:35","slug":"merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/","title":{"rendered":"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company"},"content":{"rendered":"
\n

\nSecond investment in a NASDAQ company in just over ten years.<\/b><\/p>\n

FRANKFURT AM MAIN, Germany–(BUSINESS WIRE)–Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics.<\/b><\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cOur specialty-neurology focused business Merz Therapeutics has developed very well in recent years. This investment would add significantly to Merz Therapeutics growth strategy and expand our portfolio in the field of movement disorders and neurodegeneration. In addition, it will strengthen the market position in North America\u201d says J\u00f6rg Bergler, COO of the Merz Group. “We are excited about the development of Merz Therapeutics and are convinced that the purchase of the two drugs – one for the treatment of OFF phases of Parkinson’s disease (PD) and one for the treatment of gait disorders in multiple sclerosis – would be of great value to both physicians and patients.”<\/p>\n

\nThe acquisition will be processed through a court structured 363 sale process under the U.S. Bankruptcy Code, where Merz Therapeutics will provide the opening in the auction. The purchase price offered by Merz is USD 185 million. The completion of the sale process is expected in June 2024, with any sale subject to court approval.<\/p>\n

\nFor the family-owned Merz Group, headquartered in Frankfurt, this investment would be the third transaction in the US in just over 10 years and the second time with a NASDAQ-listed company. “Merz has grown strongly in recent years – organically, but also through strategic acquisitions, especially in North America. We have solid experience in both the acquisition and integration of US companies or products. As a German-based but global company, we are very interested in innovative acquisitions, on a global scale,” concludes J\u00f6rg Bergler.<\/p>\n

\nStefan K\u00f6nig, CEO of Merz Therapeutics, adds, \u201cAs a patient-focused, innovative company we recognize the responsibility of providing continued patient care and support for Acorda\u2019s well-established and innovative therapies and see this as an optimal potential portfolio expansion that underscores our ambition in key therapeutic areas.\u201d<\/p>\n

\nAbout Merz Group
\n
<\/b>Merz Group is a global, diversified company in the healthcare sector based in Frankfurt, Germany. Family-owned for over 116 years, the company is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 4,337 people (as of the 22\/23 financial year) in 28 countries worldwide. To learn more, please visit www.merz.com<\/a>.<\/p>\n

\nAbout Merz Therapeutics
\n
<\/b>Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients\u2019 quality of life.<\/p>\n

\nMerz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group. Please visit www.merztherapeutics.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/b>
Merz Asset Management Holding GmbH & Co. KG<\/b>
Communications
\n
Karolina Dzeko-Balke
\n
Telephone number: +49 (0) 69 1503 2749
\n
E-mail: karolina.dzeko-balke@merz.de<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Second investment in a NASDAQ company in just over ten years. FRANKFURT AM MAIN, Germany–(BUSINESS WIRE)–Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics. \u201cOur … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59135","6":"format-standard","7":"category-industry"},"yoast_head":"\nMerz Enters Asset Purchase Agreement With a US-Based Biotech Company - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Second investment in a NASDAQ company in just over ten years. FRANKFURT AM MAIN, Germany–(BUSINESS WIRE)–Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics. \u201cOur ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-02T08:03:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240401849394\/en\/724308\/22\/merz_logo_Pantone_300.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company\",\"datePublished\":\"2024-04-02T08:03:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/\"},\"wordCount\":566,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240401849394\\\/en\\\/724308\\\/22\\\/merz_logo_Pantone_300.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/\",\"name\":\"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240401849394\\\/en\\\/724308\\\/22\\\/merz_logo_Pantone_300.jpg\",\"datePublished\":\"2024-04-02T08:03:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240401849394\\\/en\\\/724308\\\/22\\\/merz_logo_Pantone_300.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240401849394\\\/en\\\/724308\\\/22\\\/merz_logo_Pantone_300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/","og_locale":"en_US","og_type":"article","og_title":"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company - Pharma Trend","og_description":"Second investment in a NASDAQ company in just over ten years. FRANKFURT AM MAIN, Germany–(BUSINESS WIRE)–Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics. \u201cOur ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/","og_site_name":"Pharma Trend","article_published_time":"2024-04-02T08:03:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240401849394\/en\/724308\/22\/merz_logo_Pantone_300.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company","datePublished":"2024-04-02T08:03:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/"},"wordCount":566,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240401849394\/en\/724308\/22\/merz_logo_Pantone_300.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/","url":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/","name":"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240401849394\/en\/724308\/22\/merz_logo_Pantone_300.jpg","datePublished":"2024-04-02T08:03:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240401849394\/en\/724308\/22\/merz_logo_Pantone_300.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240401849394\/en\/724308\/22\/merz_logo_Pantone_300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/merz-enters-asset-purchase-agreement-with-a-us-based-biotech-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Merz Enters Asset Purchase Agreement With a US-Based Biotech Company"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59135"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59135\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}